Stability of ready-to-use temsirolimus infusion solution (100mg/L) in polypropylene containers under different storage conditions

Poujol, Sylvain; Bressolle, Françoise; Solassol, Isabelle; Pinguet, Frédèric

doi:10.1016/j.pharma.2012.03.005

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibitors of mTOR were mainly analysed in biological matrices even if some methods were published for their determination in solution or in pharmaceutical formulations, as in the case of stability studies or for quality control purposes. [567][568][569][570] Their narrow therapeutic window and highly variable blood levels (for the same administered dose) make mTOR inhibitors analysis in whole blood essential (mTOR inhibitors are concentrated in the red blood cells). In recent years, many analytical methods have been reported for the analysis of mTOR inhibitors in biological samples.…”

Section: Mtor Inhibitorsmentioning

confidence: 99%

Antineoplastic drugs and their analysis: a state of the art review

Guichard

Guillarme

Bonnabry

et al. 2017

Analyst

View full text Add to dashboard Cite

The number of patients suffering from cancer is constantly increasing and, consequently, the number of different chemotherapy treatments administered is increasing. Given the high reactivity and toxicity of antineoplastic drugs, analytical methods are required in all pharmaceutical fields, from drug development to their elimination in wastewater; including formulation quality control, environment and human exposure and therapeutic drug monitoring. The aim of this paper is to provide an overview of the analytical methods available for the determination of antineoplastic drugs in different matrices such as pharmaceutical formulations, biological and environmental samples. The applicability and performance of the reported methods will be critically discussed, with focus on the most commonly used antineoplastic drugs. Only conventional compounds and small molecules for targeted therapy will be considered in the present review.

show abstract

Section: Mtor Inhibitorsmentioning

confidence: 99%

Antineoplastic drugs and their analysis: a state of the art review

Guichard

Guillarme

Bonnabry

et al. 2017

Analyst

View full text Add to dashboard Cite

show abstract

SFPO and ESOP recommendations for the practical stability of anticancer drugs: An update

Vigneron¹,

Astier

Trittler

et al. 2013

Annales Pharmaceutiques Françaises

View full text Add to dashboard Cite

SFPO and ESOP recommendations for the practical stability of anticancer drugs: second update

D'Huart,

Astier,

Bardin

et al. 2024

European Journal of Oncology Pharmacy

View full text Add to dashboard Cite

A second update of the recommendations for the practical stability of anticancer drugs published in 2013 has been realized by the French Society of Hospital Pharmacists (SFPO); European Society of Oncology Pharmacists (ESOP); and members of the Stabilis® database (www.stabilis.org), a stability and compatibility database of drugs. Forty-six new molecules have been included. These new data make it possible to optimize anticancer drug preparations and achieve product savings. These new recommendations have to be taken into consideration only if the preparation is made according to the Good Manufacturing Practices in classified rooms.

show abstract

Stability of ready-to-use temsirolimus infusion solution (100mg/L) in polypropylene containers under different storage conditions

Cited by 3 publications

References 21 publications

Antineoplastic drugs and their analysis: a state of the art review

Antineoplastic drugs and their analysis: a state of the art review

SFPO and ESOP recommendations for the practical stability of anticancer drugs: An update

SFPO and ESOP recommendations for the practical stability of anticancer drugs: second update

Contact Info

Product

Resources

About